Tyrosinosis

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

C
CENTOGENEGermany - Rostock
1 program
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)N/A1 trial
Active Trials
NCT03284658Withdrawn0Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CENTOGENEBiomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)

Clinical Trials (1)

NCT03284658CENTOGENEBiomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)

Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)

Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space